LON:SUMM

Summit Therapeutics (SUMM) Share Price, News & Analysis

GBX 20.50
0.00 (0.00%)
(As of 02/21/2020)
Today's Range
18
20.50
50-Day Range
20.50
20.50
52-Week Range
18
32.50
Volume
280,318 shs
Average Volume
382,504 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
SUMM stock logo

About Summit Therapeutics Stock (LON:SUMM)

Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). The company's lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials. It has strategic alliance with the University of Oxford to develop utrophin modulators. The company was formerly known as Summit Corporation plc and changed its name to Summit Therapeutics plc in February 2015. Summit Therapeutics plc was founded in 2003 and is based in Abingdon, the United Kingdom.

SUMM Stock Price History

SUMM Stock News Headlines

2024 DTA Summit Agenda is LIVE!!
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Thousands of investors use this no cost solution | Do you?
In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.
Coave Therapeutics to Present at Upcoming Conferences
CRBP Mar 2024 30.000 put
See More Headlines
Receive SUMM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Summit Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
6/12/2019
Today
4/23/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Drugs - Generic
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Glyn O. Edwards (Age 63)
    CEO & Exec. Director
  • Mr. Erik Ostrowski (Age 46)
    Chief Financial Officer
  • Prof. David Roblin (Age 53)
    COO, Chief Medical Officer and Pres of R&D
  • Prof. Kay Davies (Age 69)
    Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor
  • Ms. Michelle Avery
    Director of Investor Relations

SUMM Stock Analysis - Frequently Asked Questions

How have SUMM shares performed in 2024?

Summit Therapeutics' stock was trading at GBX 20.50 at the start of the year. Since then, SUMM stock has increased by 0.0% and is now trading at GBX 20.50.
View the best growth stocks for 2024 here
.

How were Summit Therapeutics' earnings last quarter?

Summit Therapeutics PLC (LON:SUMM) posted its quarterly earnings data on Wednesday, June, 12th. The company reported ($3.00) EPS for the quarter, beating the consensus estimate of ($4.00) by $1.00.

What other stocks do shareholders of Summit Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Summit Therapeutics investors own include Summit Therapeutics (SMMT), American Airlines Group (AAL), Acadia Healthcare (ACHC), Diana Shipping (DSX), 2570 (JLF.L) (JLF), National Fuel Gas (NFG), Tailored Brands (TLRD), The Weir Group (WEIR) and Acacia Mining (ABGLF).

How do I buy shares of Summit Therapeutics?

Shares of SUMM stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:SUMM) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners